LLY
988.07
+2.29%↑
JNJ
193.84
+3.17%↑
UNH
327.41
+1.82%↑
NVS
130.21
+2.49%↑
TMO
586.32
+1.79%↑
LLY
988.07
+2.29%↑
JNJ
193.84
+3.17%↑
UNH
327.41
+1.82%↑
NVS
130.21
+2.49%↑
TMO
586.32
+1.79%↑
LLY
988.07
+2.29%↑
JNJ
193.84
+3.17%↑
UNH
327.41
+1.82%↑
NVS
130.21
+2.49%↑
TMO
586.32
+1.79%↑
LLY
988.07
+2.29%↑
JNJ
193.84
+3.17%↑
UNH
327.41
+1.82%↑
NVS
130.21
+2.49%↑
TMO
586.32
+1.79%↑
LLY
988.07
+2.29%↑
JNJ
193.84
+3.17%↑
UNH
327.41
+1.82%↑
NVS
130.21
+2.49%↑
TMO
586.32
+1.79%↑
24h
Current
Min
Max
Income | -75M -544K |
|---|---|
Sales | 182K 26M |
P/E Sector Avg | 19.362 77.256 |
Profit margin | -2.087 |
Employees | 59 |
EBITDA | 75M 4.1M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +152.75% upside |
Market Cap | -61M 512M |
|---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 23 USD 152.75%
High 26 USD
Low 18 USD
Based on 7 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
7 ratings
7
Buy
0
Hold
0
Sell
Based on 7 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$